CRL vs GLRE · rev $2.00B vs P/E 10, rev $327.1M
Charles River Laboratories (CRL) versus Greenlight Capital Re Ltd (GLRE) — a side-by-side from cached financials, not a winner call.
Charles River Laboratories (CRL) is a diagnostics & research company listed on US.
Greenlight Capital Re Ltd (GLRE) is a insurance - reinsurance company listed on US.
Latest reported CRL revenue for 2026-06-27 was $2.00B. Net income was -$16.3M. CRL currently screens at market cap $7.78B.
Latest reported GLRE revenue for 2026-06-30 was $327.1M. Net income was $6.2M. Revenue was up 72.5% from 2026-03-31 to 2026-06-30. GLRE currently screens at market cap $478.2M and trailing P/E 10.5.
CRL currently screens at market cap $7.78B. GLRE currently screens at market cap $478.2M and trailing P/E 10.5.
Not investment advice. Open the CRL and GLRE stock pages for the full models.
Not investment advice.